17026-Breast Cancer-NA-457

Breast Cancer

BYLieve: A phase II, multicenter, open-label, three-cohort, noncomparative study to assess the efficacy and safety of alpelisib plus fulvestrant or letrozole in patients with PIK3CA mutant,hormone receptor (HR) positive, HER2-negative advanced breast cancer (aBC), who have progressed on or after prior treatments (CBYL719X2402)

  • Details

ClinicalTrials.gov ID: NCT03056755
Diagnosis Type: NA
USOR Number: 17026

  • Address

3705 West 15th Street
Plano, TX 75075
P: (972) 867-3577

Find a Clinical Trial

Search by practice name, trial titles, indicators and specific disease types.